Comparative Pharmacology
Head-to-head clinical analysis: ANDROID 5 versus METHYLTESTOSTERONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANDROID 5 versus METHYLTESTOSTERONE.
ANDROID 5 vs METHYLTESTOSTERONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Androgen receptor agonist; stimulates protein synthesis and growth of androgen-sensitive tissues.
Methyltestosterone is a synthetic androgen that binds to and activates androgen receptors (AR) in target tissues, promoting the development and maintenance of male secondary sexual characteristics and anabolic effects. It also suppresses gonadotropin-releasing hormone (GnRH) secretion via negative feedback, reducing endogenous testosterone production.
2.5-10 mg orally once daily in the morning for androgen replacement therapy in adult males.
10-50 mg orally once daily or divided twice daily, or 10-25 mg buccally twice daily.
None Documented
None Documented
Clinical Note
moderateMethyltestosterone + Digoxin
"Methyltestosterone may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateMethyltestosterone + Digitoxin
"Methyltestosterone may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateMethyltestosterone + Deslanoside
"Methyltestosterone may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateMethyltestosterone + Acetyldigitoxin
Terminal elimination half-life is 3.5–5.5 hours; clinical effects may persist for several days due to active metabolites.
2-4 hours (terminal); requires multiple daily dosing or transdermal route due to short half-life.
Primarily renal: ~90% as glucuronide and sulfate conjugates, 6% as unchanged drug; ~5% fecal via bile.
Renal (primarily as glucuronide and sulfate conjugates, ~90%); fecal (~10%). Unchanged drug is minimal.
Category C
Category D/X
Androgen
Androgen
"Methyltestosterone may decrease the cardiotoxic activities of Acetyldigitoxin."